Aratana Therapeutics, Inc. (NASDAQ:PETX) has been given a consensus rating of “Hold” by the nine ratings firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $10.40.

Several brokerages have recently commented on PETX. BidaskClub downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 25th. Zacks Investment Research downgraded Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Aratana Therapeutics in a research note on Sunday, May 14th.

COPYRIGHT VIOLATION WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/08/aratana-therapeutics-inc-petx-given-consensus-rating-of-hold-by-analysts.html.

Several institutional investors have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC raised its position in Aratana Therapeutics by 7.9% in the second quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 1,200 shares in the last quarter. American International Group Inc. raised its position in Aratana Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,354 shares in the last quarter. Geneva Advisors LLC raised its position in Aratana Therapeutics by 3.7% in the second quarter. Geneva Advisors LLC now owns 80,118 shares of the biopharmaceutical company’s stock valued at $579,000 after buying an additional 2,830 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its position in Aratana Therapeutics by 17.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 3,883 shares in the last quarter. Finally, Weiss Multi Strategy Advisers LLC raised its position in Aratana Therapeutics by 8.3% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 65,000 shares of the biopharmaceutical company’s stock valued at $345,000 after buying an additional 5,000 shares in the last quarter. 67.85% of the stock is owned by institutional investors.

Shares of Aratana Therapeutics (NASDAQ:PETX) traded down 0.96% during midday trading on Tuesday, reaching $6.20. The company had a trading volume of 262,143 shares. The stock’s 50 day moving average is $7.07 and its 200-day moving average is $6.46. Aratana Therapeutics has a 12-month low of $4.97 and a 12-month high of $10.73. The stock’s market capitalization is $235.33 million.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.03. The firm had revenue of $5.16 million during the quarter, compared to the consensus estimate of $4.50 million. Aratana Therapeutics had a negative return on equity of 52.00% and a negative net margin of 642.93%. The company’s quarterly revenue was down 86.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.61 earnings per share. On average, equities research analysts predict that Aratana Therapeutics will post ($1.04) earnings per share for the current fiscal year.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.